Saturna Capital Corp Bio N Tech Se Transaction History

Saturna Capital Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $543,129 - $689,691	-5,514 Reduced 73.19%	2,020 $219,000
Q2 2023 Aug 04, 2023	SELL	$102.58 - $129.66 $17,541 - $22,171	-171 Reduced 2.22%	7,534 $813,000
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $108,229 - $135,690	883 Added 12.94%	7,705 $959,000
Q4 2022 Feb 09, 2023	BUY	$118.43 - $186.05 $535,540 - $841,318	4,522 Added 196.61%	6,822 $1.02 Million
Q3 2022 Nov 10, 2022	BUY	$127.65 - $183.11 $293,595 - $421,153	2,300 New	2,300 $310,000
Q1 2022 May 10, 2022	SELL	$126.25 - $231.85 $290,375 - $533,255	-2,300 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $197,179 - $274,850	2,300 New	2,300 $251,000

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $27.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Saturna Capital Corp, based on Form 13F filings with the SEC.

Stay updated on Saturna Capital Corp with notifications on news.